Literature DB >> 27185609

Phenotypes of prediabetes and stratification of cardiometabolic risk.

Norbert Stefan1, Andreas Fritsche2, Fritz Schick3, Hans-Ulrich Häring2.   

Abstract

Prediabetes is associated with increased risks of type 2 diabetes, cardiovascular disease, dementia, and cancer, and its prevalence is increasing worldwide. Lifestyle and pharmacological interventions in people with prediabetes can prevent the development of diabetes and possibly cardiovascular disease. However, prediabetes is a highly heterogeneous metabolic state, both with respect to its pathogenesis and prediction of disease. Improved understanding of these features and precise phenotyping of prediabetes could help to improve stratification of disease risk. In this Personal View, we focus on the extreme metabolic phenotypes of metabolically healthy obesity and metabolically unhealthy normal weight, insulin secretion failure, insulin resistance, visceral obesity, and non-alcoholic fatty liver disease. We present new analyses aimed at improving characterisation of phenotypes in lean, overweight, and obese people with prediabetes. We discuss evidence from lifestyle intervention studies to explore whether these phenotypes can also be used for individualised prediction and prevention of cardiometabolic diseases.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27185609     DOI: 10.1016/S2213-8587(16)00082-6

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN: 2213-8587            Impact factor:   32.069


  47 in total

Review 1.  The Vasculature in Prediabetes.

Authors:  David H Wasserman; Thomas J Wang; Nancy J Brown
Journal:  Circ Res       Date:  2018-04-13       Impact factor: 17.367

2.  Trends in Prevalence of Nonalcoholic Fatty Liver Disease in US Adults with Prediabetes.

Authors:  Phuc Le; Alexander Chaitoff; Michael B Rothberg; Naim Alkhouri; Arthur McCullough
Journal:  J Gen Intern Med       Date:  2019-11       Impact factor: 5.128

3.  Non-alcoholic fatty liver disease and impaired proinsulin conversion as newly identified predictors of the long-term non-response to a lifestyle intervention for diabetes prevention: results from the TULIP study.

Authors:  Vera Schmid; Robert Wagner; Corinna Sailer; Louise Fritsche; Konstantinos Kantartzis; Andreas Peter; Martin Heni; Hans-Ulrich Häring; Norbert Stefan; Andreas Fritsche
Journal:  Diabetologia       Date:  2017-08-24       Impact factor: 10.122

Review 4.  Global pandemics interconnected - obesity, impaired metabolic health and COVID-19.

Authors:  Norbert Stefan; Andreas L Birkenfeld; Matthias B Schulze
Journal:  Nat Rev Endocrinol       Date:  2021-01-21       Impact factor: 43.330

Review 5.  Excess Body Weight and Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD).

Authors:  Elke Roeb
Journal:  Visc Med       Date:  2021-04-13

Review 6.  [New aspects of nonalcoholic steatohepatitis].

Authors:  N Stefan
Journal:  Internist (Berl)       Date:  2019-02       Impact factor: 0.743

Review 7.  The Metabolic Phenotype in Obesity: Fat Mass, Body Fat Distribution, and Adipose Tissue Function.

Authors:  Gijs H Goossens
Journal:  Obes Facts       Date:  2017-06-01       Impact factor: 3.942

Review 8.  Probiotics and prebiotics in intestinal health and disease: from biology to the clinic.

Authors:  Mary Ellen Sanders; Daniel J Merenstein; Gregor Reid; Glenn R Gibson; Robert A Rastall
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-07-11       Impact factor: 46.802

9.  Rationale and Design of RNAFH Study: Effect of Rosuvastatin (10 mg/d) on Nonalcoholic Fatty Liver in Metabolic Syndrome Patients without Overt Diabetes Evaluated by 1H-Magnetic Resonance Spectroscopy.

Authors:  Fan Ping; Xuan Wang; Jing Yang; Mei-Cen Zhou; Wei Li; Ling-Ling Xu; Yu-Xiu Li
Journal:  Int J Endocrinol       Date:  2016-10-19       Impact factor: 3.257

10.  Prevalence of Prediabetes and Undiagnosed Diabetes Among Kuwaiti Adults: A Cross-Sectional Study.

Authors:  Anwar Mohammad; Ali H Ziyab; Talal Mohammad
Journal:  Diabetes Metab Syndr Obes       Date:  2021-05-17       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.